GU Cancers 2023 | Immunotherapy combined with new treatments suggested as the future of aRCC therapy

Anand Sharma, MD, D.Phil, MRCP, MBBS, Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Northwood, UK, discusses the future of advanced renal cell cancer (aRCC) therapies. Dr Sharma notes the promise of tyrosine kinase inhibitors (TKIs) but suggests combination therapies using immunotherapy as a base will be the most effective treatments. This interview took place at the American Clinical Society of Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.